Overview

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.
Phase:
N/A
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
Novartis Pharmaceuticals
Treatments:
Diphosphonates
Teriparatide
Zoledronic Acid